I may be reading too much into the PR. However, it seems to me that Dr. Jay is sending a positive message to shareholders and reminding potential stakeholders as to the progress Cytodyn has made.

"The stockholders deserve this finality..."

"especially exciting moment for the company"

"Phase II studies moving forward in metastatic colorectal cancer and metastatic triple negative breast cancer and the progress with our Expanded Access Program...

"we are more optimistic than ever about leronlimab's potential to benefit cancer patients who struggle with limited treatment options."

NP couldn't and wouldn't have said it any better.

Jacob Lalezari, M.D., CEO of CytoDyn, added, “Bringing closure to this matter has been a priority since I was hired as CEO. The stockholders deserve this finality, and we are pleased to achieve a resolution that reinforces our stability and allows us to pursue our mission. It comes at an especially exciting moment for the company, as a growing body of clinical evidence continues to validate the scientific promise of leronlimab. With new Phase II studies moving forward in metastatic colorectal cancer and metastatic triple-negative breast cancer, and the progress with our Expanded Access Program, we are more optimistic than ever about leronlimab’s potential to benefit cancer patients who struggle today with limited treatment options.”